1. Introduction
1.1. Market Overview
1.2. Scope of the Study
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Plasma Fractionation Market Analysis, By Application
5.1. Introduction
5.2. Neurology
5.3. Immunology
5.4. Hematology
5.5. Pulmonology
6. Plasma Fractionation Market Analysis, By End User
6.1. Introduction
6.2. Hospitals & Clinics
6.3. Academic & Research Institutes
7. Plasma Fractionation Market Analysis, By Geography
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. UK
7.4.2. France
7.4.3. Germany
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. Japan
7.6.2. China
7.6.3. India
7.6.4. South Korea
7.6.5. Thailand
7.6.6. Taiwan
7.6.7. Indonesia
7.6.8. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Octapharma AG
9.2. GE Healthcare
9.3. Merck KGaA
9.4. Grifols SA
9.5. CSL Ltd.
9.6. Biotest
9.7. Sanquin
9.8. Takeda Pharmaceutical Company
9.9. Kedrion
9.10. Bio Products Laboratory